Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $330.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price raised by investment analysts at Piper Sandler from $310.00 to $330.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Piper Sandler‘s target price would suggest a potential upside of 32.94% from the stock’s previous close.

A number of other brokerages have also recently commented on JAZZ. The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $337.00 target price on the stock. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $220.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday. TD Cowen boosted their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, UBS Group increased their target price on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $294.00.

Jazz Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ JAZZ opened at $248.24 on Thursday. Jazz Pharmaceuticals has a one year low of $136.27 and a one year high of $266.38. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.64. The firm’s 50 day simple moving average is $229.35 and its two-hundred day simple moving average is $218.88. The stock has a market capitalization of $15.93 billion, a P/E ratio of 21.76, a PEG ratio of 0.45 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same period in the previous year, the business posted $8.13 EPS. The business’s quarterly revenue was up 10.4% on a year-over-year basis. As a group, analysts expect that Jazz Pharmaceuticals will post 11.08 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,413 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total transaction of $326,911.68. Following the completion of the transaction, the chief accounting officer directly owned 6,512 shares of the company’s stock, valued at approximately $1,506,616.32. This represents a 17.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 171,342 shares of company stock worth $41,420,491 over the last ninety days. 4.10% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Several large investors have recently modified their holdings of JAZZ. TIAA CREF Individual & Institutional Services LLC bought a new position in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $310,000. Advisors Asset Management Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $773,000. Private Advisor Group LLC increased its stake in shares of Jazz Pharmaceuticals by 193.2% during the third quarter. Private Advisor Group LLC now owns 3,046 shares of the specialty pharmaceutical company’s stock valued at $705,000 after buying an additional 2,007 shares during the period. Ieq Capital LLC increased its stake in shares of Jazz Pharmaceuticals by 1,149.2% during the third quarter. Ieq Capital LLC now owns 20,625 shares of the specialty pharmaceutical company’s stock valued at $4,775,000 after buying an additional 18,974 shares during the period. Finally, Focus Advisor Solutions LLC increased its stake in shares of Jazz Pharmaceuticals by 75.2% during the third quarter. Focus Advisor Solutions LLC now owns 2,802 shares of the specialty pharmaceutical company’s stock valued at $649,000 after buying an additional 1,203 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.